After finishing at $15.88 in the prior trading day, Immunovant Inc. (NASDAQ: IMVT) closed at $15.41, down -2.96%. In other words, the price has decreased by -$0.47 from its previous closing price. On the day, 534699 shares were traded. IMVT stock price reached its highest trading level at $15.83 during the session, while it also had its lowest trading level at $15.37.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Our goal is to gain a better understanding of IMVT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.00 and its Current Ratio is at 11.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 15, 2023, initiated with a Overweight rating and assigned the stock a target price of $30.
On February 13, 2023, Guggenheim Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $30.
Wells Fargo Upgraded its Equal Weight to Overweight on January 03, 2023, whereas the target price for the stock was revised from $10 to $27.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 02 when Macias William L. sold 537 shares for $18.24 per share. The transaction valued at 9,795 led to the insider holds 262,996 shares of the business.
Levine Mark S. sold 10,156 shares of IMVT for $187,988 on Jan 26. The Chief Legal Officer now owns 245,660 shares after completing the transaction at $18.51 per share. On Jan 11, another insider, Butchko Julia G., who serves as the Chief Dev. & Tech. Officer of the company, sold 60,490 shares for $16.79 each. As a result, the insider received 1,015,596 and left with 331,419 shares of the company.
Stock Price History:
Over the past 52 weeks, IMVT has reached a high of $20.24, while it has fallen to a 52-week low of $3.14. The 50-Day Moving Average of the stock is 17.75, while the 200-Day Moving Average is calculated to be 10.42.
The stock has traded on average 1.09M shares per day over the past 3-months and 752.08k shares per day over the last 10 days, according to various share statistics. A total of 128.57M shares are outstanding, with a floating share count of 53.32M. Insiders hold about 59.50% of the company’s shares, while institutions hold 33.30% stake in the company. Shares short for IMVT as of Jan 30, 2023 were 2.32M with a Short Ratio of 3.43M, compared to 3.6M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 1.78% and a Short% of Float of 4.14%.
Its stock is currently analyzed by 9 different market analysts. On average, analysts expect EPS of -$0.41 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.53, while EPS last year was -$0.41. The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.39 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.4 and -$1.69 for the fiscal current year, implying an average EPS of -$1.61. EPS for the following year is -$1.65, with 9 analysts recommending between -$1.41 and -$1.94.